肝功能失代偿是丙型肝炎病毒感染合并肝硬化且早期肝细胞癌成功治疗患者死亡的主要驱动因素
研究前瞻性纳入328例HCV相关肝硬化且BCLC 0/A期肝细胞癌经根治性切除或热消融后达到完全影像学缓解的患者,5年总生存率为44%,早期肝细胞癌复发率和早期肝功能失代偿率分别为21%和10%。早期肝功能失代偿(HR 7.52;95%CI 1.23-13.48)、早期肝细胞癌复发(HR 2.50;95%CI 1.23-5.05)、基线食管静脉曲张(HR 1.66;95%CI 1.02-2.70)和年龄(HR 1.04;95%CI 1.02-1.07)与5年总生存率显著相关。
要点
- HCV相关肝硬化合并BCLC 0/A期肝细胞癌成功治疗后5年生存率为44%。
- 早期肝功能失代偿(HR 7.52)和早期肝细胞癌复发(HR 2.50)与5年总生存率显著相关。
- 基线食管静脉曲张和年龄也是5年总生存率的独立预测因素。
核心结论
- HCV感染合并肝硬化且肝细胞癌成功治疗患者的生存受早期肝功能失代偿影响。
- 研究间接提示直接抗病毒药物可能通过长期保护肝功能改善肝细胞癌患者的总生存率。
研究设计与样本
- 前瞻性招募328例连续的白种人HCV相关肝硬化且BCLC 0/A期肝细胞癌患者,经根治性切除或热消融后达到完全影像学缓解。
- 主要终点为5年总生存率,采用Cox模型识别独立的基线和时间依赖性预测因素。
主要发现
- 观察到的5年生存率为44%。
- 观察到的早期肝细胞癌复发率和早期肝功能失代偿率分别为21%和10%。
- 早期肝功能失代偿作为时间依赖性协变量与5年总生存率显著相关(HR 7.52;95%CI 1.23-13.48)。
- 早期肝细胞癌复发作为时间依赖性协变量与5年总生存率显著相关(HR 2.50;95%CI 1.23-5.05)。
- 基线食管静脉曲张(HR 1.66;95%CI 1.02-2.70)和年龄(HR 1.04;95%CI 1.02-1.07)与5年总生存率显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. METHODS: A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BCLC stage 0/A HCC who had complete radiological response after curative resection or thermal ablation were prospectively recruited to this study. Primary endpoint of the study was 5-year OS. Independent baseline and time-dependent predictors of 5-year OS were identified by Cox model. RESULTS: The observed 5-year survival rate was 44%. The observed HCC early recurrence and early hepatic decompensation rate were 21% and 10%, respectively. Early hepatic decompensation (Hazard Ratio [HR] 7.52; 95% confidence intervals (CI): 1.23-13.48) and HCC early recurrence as time-dependent covariates (HR 2.50; 95%CI: 1.23-5.05), presence of esophageal varices at baseline (HR 1.66; 95% CI: 1.02-2.70) and age (HR 1.04; 95% CI: 1.02-1.07) were significantly associated with the 5-year OS. CONCLUSION: Survival in HCV-infected patients with cirrhosis and successfully treated HCC is influenced by early hepatic decompensation. Our study indirectly suggests that direct-acting antiviral agents could improve OS of HCC patients through long-term preservation of liver function, resulting in a lower cirrhosis-related mortality and a greater change of receiving curative treatments. LAY SUMMARY: Survival in hepatitis C virus (HCV) infected patients with cirrhosis and successfully treated hepatocellular carcinoma (HCC), is mainly influenced by early hepatic decompensation. HCV eradication after treatment with new direct-acting antiviral agents could improve overall survival of HCC patients through long-term preservation of liver function.
引用
- Cabibbo G, Petta S, Barbara M, et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017. PMID: 28192185. doi:10.1016/j.jhep.2017.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。